Enrolling by invitationPhase 2NCT06547216

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Studying Facioscapulohumeral dystrophy

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Avidity Biosciences, Inc.
Principal Investigator: Amy Halseth, Ph.D.
Avidity Biosciences, Inc.
Intervention: AOC 1020(drug)
Enrollment: 84 enrolled
Eligibility: 16-70 years · All sexes
Timeline: 2024 – 2028

Study locations (17)

University of California Los Angeles, Los Angeles, California, United States
Stanford University, Palo Alto, California, United States
University of California San Diego, San Diego, California, United States
University of Colorado, Denver, Colorado, United States
University of Florida, Gainesville, Florida, United States
Rare Disease Research, Atlanta, Georgia, United States
Kansas University Medical Center, Kansas City, Kansas, United States
University of Rochester Medical Center, Rochester, New York, United States
Duke University, Durham, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Texas Southwestern, Dallas, Texas, United States
Virginia Commonwealth University, Richmond, Virginia, United States
University of Washington, Seattle, Washington, United States
University of Ottawa, Ottawa, Ontario, Canada
+2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06547216 on ClinicalTrials.gov

Other trials for Facioscapulohumeral dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Facioscapulohumeral dystrophy →

← Back to all trials